• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
MSB

MESOBLAST LIMITED - News & Media

2.97% ! $1.80
Market Cap $2.293B  !
Healthcare Biotechnology
Add to My Watchlist

Mesoblast Limited is an Australia-based company, which is engaged in developing... Mesoblast Limited is an Australia-based company, which is engaged in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. It has leveraged its proprietary mesenchymal lineage cell therapy technology platform to establish a broad portfolio of late-stage product candidates. It is developing product candidates for distinct indications based on its remestemcel-L and rexlemestrocel-L allogeneic stromal cell technology platforms. Remestemcel-L is being developed for inflammatory diseases in children and adults including steroid refractory acute graft versus host disease, and biologic-resistant inflammatory bowel disease. Rexlemestrocel-L is being developed for advanced chronic heart failure (REVASCOR) and chronic low back pain (MPC-06-ID). Two products have been commercialized in Japan and Europe by the Company's licensees. It has established commercial partnerships in Europe and China for certain Phase III assets.More

Articles & Videos

The market shrugged at Mesoblast's latest FDA win. Is it just another Droneshield?

Mesoblast (ASX:MSB) has revealed the US FDA has given its flagship drug a 7 year exclusivity period, blocking...

15 May 2025 11:20 (AEST)

Mesoblast dips on 'belief' it's not subject to US tariffs – despite Singaporean lab

Mesoblast (ASX:MSB) has seen shares fall just shy of -3% heading into lunchtime trades despite apparent tariff relief.

04 Apr 2025 12:31 (AEDT)

Mesoblast kicks off treatment for first 3 kids with graft-host disease. So why are shares down?

otCopper favourite Mesoblast (ASX:MSB) has announced it's begun treating the first 3 children with skin graft-versus-host disease in the US, at the same time the company received medicare (US) and medicaid coverage.

31 Mar 2025 12:55 (AEDT)

Mesoblast kicks off Ryoncil sales in US but shareholders eager for revenue

Mesoblast (ASX:MSB) has announced its product Ryoncil is officially available for sale in the US through private health insurance.

27 Mar 2025 11:57 (AEDT)

HotCopper users flock to make sense of darling Mesoblast's 'proposed financing'

If you’ve been paying attention, you know Mesoblast (ASX:MSB) is currently something of an Australian market darling.Just take a look at its recent run. One-year returns are currently up +868%, borne largely from the US FDA’s decision to approve Mesoblast&CloseCurl...

10 Jan 2025 12:44 (AEDT)

Gold Medal Awards: All the biggest ASX winners (and top stock gainers) in 2024

The ASX is barrelling towards closing out 2024 with another red day on New Year’s Eve, but that doesn’t mean the year as a whole was a bloodbath @ in fact, for much of the Aussie index it’s been quite the year to remember.Even more so, some Australi...

31 Dec 2024 11:40 (AEDT)

Cashed up & ready to go: Mesoblast forges funding deal with top shareholder

Mesoblast (ASX:MSB) is trading up more than 1.75% after striking a funding deal with its largest shareholder Gregory George for AUD$72.7 million in convertible notes.

30 Sep 2024 11:20 (AEST)

Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%

Mesoblast shares fell -4.45% in the first hour of trades on Tuesday as the company announced it has to resubmit an application to the FDA.

09 Jul 2024 10:43 (AEST)

Mesoblast (ASX:MSB) completes $97M funding round heading into Q2

Mesoblast (ASX:MSB) has completed its pro-rata accelerated non-renounceable entitlement offer, launched on December 4, 2023.

14 Mar 2024 13:59 (AEDT)

Mesoblast (ASX:MSB) gains FDA approval to fast-track Revascor in end-stage heart failure

Mesoblast (ASX:MSB) has received U.S. FDA approval to accelerate rexlemestrocel-L (Revascor) for patients with end-stage ischemic heart failure and reduced ejection fraction (HFrEF) with a left ventricular assist device (LVAD).

11 Mar 2024 12:12 (AEDT)



Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
Add to My Watchlist
(20min delay)
Last
$1.80 		Change
-0.055(2.97%) 		Mkt cap ! $2.293B
Open High Low Value Volume
$1.84 $1.86 $1.77 $7.241M 4.018M

Buyers (Bids)

No. Vol. Price($)
3 25472 $1.80
 

Sellers (Offers)

Price($) Vol. No.
$1.81 1500 1
View Market Depth
Last trade - 16.10pm 13/06/2025 (20 minute delay) ?
MSB (ASX) Chart

Top Stories

Zip's stunning comeback: Is this the start of a $14 revival?

Just when the market had written it off… Zip Co (ASX: ZIP) has come roaring back to life. The Buy Now, Pay Later company stunned investors last Wednesday with a 15% surge in its share price soon after upgrading its full-year earnings forecast to at least $160 million @ up from $153 million...
'Sure to be busy': Advance's Yuquivo drilling gets off to top start with first-hole hits Advance Metals (ASX:AVM) has started its maiden drilling at the Yoquivo Silver-Gold Project in Mexico with a bang...
Clinuvel shares dip, even as CEO comes back from temp leave After Clinuvel's (ASX:CUV) CEO Dr. Philippe Wolgen took time off back in March to respond to an "acute medical condition," it wasn't...
Week 24 Wrap: WW3 looms (again); US econ data tepid & silver surfing By and large, I don't think I'd be without peers when I said the biggest thing that happened this week was on energy markets.
HotCopper Highlights, Week 24: Israel boosts Energy; Meeka eyes production & Mag7 back Good Afternoon and welcome to HotCopper Highlights for Week 24 of the year, I’m Jon Davidson. In this segment we look at some of the...
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.